Original Article

CME Article: Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease

Authors: Cody Cichowitz, BS, Patrick C. Carroll, MD, John J. Strouse, MD, PhD, Carlton Haywood, PhD, MA, Sophie Lanzkron, MD, MHS

Abstract

Objectives: Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease.

Methods: We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant’s electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions.

Results: Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5–4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (−3.3, 95% CI −5.7 to −0.97 and −3.2, 95% CI −6.2 to −0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2–5.2) and a history of hydroxyurea therapy (2.0, 95% CI −0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (−3.3, 95% CI −6.4 to −0.24) and increased aspartate transaminase (−0.045, 95% CI −0.089 to −0.0010) were independent predictors of a decreased score.

Conclusions: The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Armstrong FD, Thompson RJ, Jr Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 1996;97(6 pt 1):864-870.
 
2. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996;17:965-972.
 
3. Wang W, Enos L, Gallagher D, et al. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001;139:391-397.
 
4. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011;117:1130-1140.
 
5. Bernaudin F, Verlhac S, Frບ F, et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J Child Neurol 2000;15:333-343.
 
6. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009;146:300-305.
 
7. Watkins KE, Hewes DK, Connelly A, et al. Cognitive deficits associated with frontal-lobe infarction in children with sickle cell disease. Dev Med Child Neurol 1998;40:536-543.
 
8. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012;119:3684-3690.
 
9. Mackin RS, Insel P, Truran D, et al. Neuroimaging abnormalities in adults with sickle cell anemia: associations with cognition. Neurology 2014;82:835-841.
 
10. Manfrè L, Giarratano E, Maggio A, et al. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 1999;173:1477-1480.
 
11. Marouf R, Gupta R, Haider MZ, et al. Silent brain infarcts in adult Kuwaiti sickle cell disease patients. Am J Hematol 2003;73:240-243.
 
12. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-294.
 
13. Silva GS, Vicari P, Figueiredo MS, et al. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease correlation with transcranial Doppler findings. Stroke 2009;40:2408-2412.
 
14. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010;303:1823-1831.
 
15. Nasreddine ZS, Phillips NA, Bຝ V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
 
16. Montreal Cognitive Assessment. www.mocatest.org. Accessed November 8, 2014.
 
17. Kenny RA, Coen RF, Frewen J, et al. Normative values of cognitive and physical function in older adults: findings from the Irish Longitudinal Study on Ageing. J Am Geriatr Soc 2013;61( 2 suppl ):S279-S290.
 
18. Rossetti HC, Lacritz LH, Cullum CM, et al. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011;77:1272-1275.
 
19. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
 
20. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006;133:570-578.
 
21. Taylor JG, 6th Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008;3:e2095.